Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,011 | 8,988 | 11,094 | 5,191 | 5,157 |
| Other current assets | 110 | 57 | 0 | 0 | 0 |
| TOTAL | $6,993 | $9,612 | $11,434 | $5,469 | $5,382 |
| Non-Current Assets | |||||
| PPE Net | 81 | 88 | 80 | 16 | 17 |
| Other Non-Current Assets | 137 | 155 | 173 | 4 | 0 |
| TOTAL | $218 | $243 | $253 | $20 | $17 |
| Total Assets | $7,211 | $9,855 | $11,687 | $5,488 | $5,399 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,680 | 1,525 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 903 | 900 | 339 | 397 | 510 |
| Accrued Expenses | 237 | 345 | 263 | 113 | 132 |
| Other current liabilities | 1,059 | 886 | 705 | 952 | 699 |
| TOTAL | $4,182 | $3,912 | $1,502 | $1,548 | $1,384 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 56 | 79 | 1,921 | 1,669 | 1,536 |
| TOTAL | $56 | $79 | $1,921 | $1,669 | $1,536 |
| Total Liabilities | $4,238 | $3,991 | $3,422 | $3,217 | $2,920 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,984 | 1,984 | 1,904 | 1,669 | 1,488 |
| Common Shares | 496 | 476 | 476 | 396 | 368 |
| Retained earnings | -50,300 | -47,256 | -44,743 | -42,919 | -40,895 |
| TOTAL | $2,973 | $5,864 | $8,265 | $2,271 | $2,479 |
| Total Liabilities And Equity | $7,211 | $9,855 | $11,687 | $5,488 | $5,399 |